GH Guardant Health, Inc.
FY2025 10-K
Guardant Health, Inc. (GH) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
- • New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
Management Discussion & Analysis
- • Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
- • Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
Risk Factors
- • Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
- • Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
Financial SummaryXBRL
Revenue
$982M
Net Income
-$416M
Operating Margin
-44.5%
Net Margin
-42.4%
ROE
419.2%
Total Assets
$2.0B
EPS (Diluted)
$-3.32
Operating Cash Flow
-$185M
Source: XBRL data from Guardant Health, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Guardant Health, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.